Skip to main content

Table 2 Diagnostic performance of PIRADS v2 alone for PCa and csPCa

From: Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer

 

PCa

csPCa

 

PI-RADs v2 (%)

Age (%)

PSAD (%)

Model 1 (%)

PI-RADs v2 (%)

Age (%)

PSAD (%)

Model 2 (%)

Sensitivity

76.6

51.8

83

85.8

85.9

78.1

78.9

87.5

Specifivity

83.6

69.2

48.9

67.9

63.5

65.3

43.7

67.1

Positive predictive value

67.9

49.7

62.2

72.9

61.6

60.5

48.9

63.1

Negative predictive value

73

69.2

73.9

82.6

86.9

81.3

72.3

84.8